Aprea Therapeutics CEO Dr Oren Gilad discusses ASCO 2026 data for WEE1 inhibitor APR-1051 and the company's precision oncology strategy while at BIO 2026.
Oren Gilad
Advertisement
Oren Gilad, PhD, is president and CEO of Aprea Therapeutics.
Articles by Oren Gilad
Speaking prior to the start of BIO 2026, Aprea Therapeutics CEO Dr Oren Gilad explains how biomarker-driven oncology strategies are advancing targeted therapies designed to improve efficacy while reducing treatment-related toxicity.
Advertisement
Latest Updated Articles
Advertisement
Advertisement